






The past few years have produced remarkable advances
in our understanding of the cutaneous immune response. A
better understanding of T-cell trafficking (reviewed in Kupper
and Fuhlbrigge, 2004), the emerging role of defensins in
innate immunity (reviewed in Oppenheim et al, 2003 and
Bardan et al, 2004), and the re-emergence of the suppres-
sor cell as the T-regulatory cell (reviewed in O’Gara and
Vieira, 2004, and Jonuleit and Schmitt, 2003) are changing
our understanding of the immunopathology of a wide variety
of cutaneous diseases and opening new opportunities to
manipulate systemic immune responses using the readily
accessible skin immune system. In some cases, new
discoveries are challenging old paradigms, forcing a recon-
sideration of previous established concepts and resulting in
a deeper understanding of cutaneous immune function.
Dendritic cells have long been recognized as key regulators
of cutaneous immunity. New evidence regarding the origin,
function, and remarkable plasticity of cutaneous dendritic
cells (DCs) provides an exciting example of evolving
paradigms in skin immunology. How can we reconcile these
new experimental results with established principles? While
a definitive discussion is well beyond the scope of this
review, we can outline some of what we know, and what we
think we know. We leave it to the reader to decide which is
which. At the present time, maybe the only clear conclusion
is that there has never been a more exciting time to be a
cutaneous immunologist. 
Skin Dendritic Cells: What’s in a Name?
Dendritic cells (DCs) were originally named based on
their characteristic stellate appearance in the skin, lymph
nodes, and spleen. The first DCs described were Langer-
hans cells, the dendritic cells of the epidermis described by
Paul Langerhans in 1868. It is now recognized that the
“dendritic” morphology of these cells, and DCs in general,
contributes to their function as key sentinels, communica-
tors, and directors of cutaneous and systemic immune
responses. As an organ that is constantly exposed to exter-
nal antigens (Ags) and environmental stress, it is logical that
the skin is richly populated by these professional Ag
processing and presenting cells (APCs). After years of
focused investigation and identification of an array of pheno-
typic markers now used to “separate” DCs into multiple
subsets, the preferred definition of DCs is still based on
function. Classically, DCs, including those resident in
peripheral tissues, have been defined by their ability to: i)
take up and process Ags in peripheral tissues where they
reside, ii) migrate and transport those Ags from periphery to
secondary lymphoid organs and iii) stimulate naïve T cells
(Banchereau and Steinman, 1998). Recent evidence argues
that an additional function, specifically their unique plasticity
and ability to serve as “biosensors”, translating environmen-
tal ques from the periphery to the lymphoid organs, should
be added to this definition. It is clear that their dendritic
shape better enables them to perform their functions. Their
“dendrites” enable both optimal sampling of their environ-
ment, and subsequently their efficient interaction with
relatively large numbers of responding T-cells in the
confined space of the lymphoid organs. Thus, the original
use of the term “dendritic cell” to name this cell type was not
only histopathologically accurate, but also remarkably
predictive of functions yet to be discovered. 
There has been a growing realization that dendritic cells
are not just important for “presenting” foreign antigens to the
immune system, but are actually the key regulators of local
and systemic immune responses. The early stages of DC-T
cell interaction are crucial to deciding the outcome of the
future immune response, or for the maintenance of periph-
eral self tolerance. During this initial interaction, DCs have
the ability to induce the differentiation of naïve CD4+ helper
T (Th) cells into Th1 cells to promote cellular immunity, or
Th2 cells to promote humoral immunity. In addition, DCs can
activate CD8+ T cells with cytotoxic function to eliminate
infected tissue or tumor cells (reviewed by Larregina and
Falo in 2000 and 2001b). Equally as important, DCs can
promote tolerance by the induction of anergy or apoptosis of
naïve T cells, or by stimulation of a population of T cells with
regulatory function (regulatory T cells: Treg) (reviewed by
Morelli et al, 2001). 
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A short history of skin resident dendritic cells:
from neurons to professional antigen 
presenting cells.
At least two populations of skin resident cells had been
considered to be dendritic cells: Langerhans cells (LCs)
resident in the epidermis, and dermal dendritic cells (or
dermal dendrocytes) (DDCs) resident in the dermis. Skin
DCs were first described as intraepithelial neurons by Paul
Langerhans and subsequently have been referred to as
Langerhans cells. Arstein in 1876 and Herxeimer in 1896
hypothesized that LCs were epidermal passenger leuco-
cytes, however they could not prove their hypothesis proba-
bly due to the technical limitations of the time (Arstein 
et al,1876; Herxeimer et al,1896). During the following years
different proposed origins and functions were given to LCs
including the possibility of their being dying melanocytes
(reviewed by Wolff in 1991). Soon after the discovery of
spleen DCs and their potent allostimulatory function (Stein-
man and Cohn, 1973), epidermal LC were considered to be
leukocytes of the immune system, involved in the develop-
ment of hypersensitivity reactions (Silberberg et al, 1976).
LCs were long considered to be skin histiocytes, and later to
be members of the mononuclear phagocytic system by
pathologists (Moschella et al.1990). This evolution gave rise
to the origin of terms such as hystiocytosis X and LC histio-
cytoma (LCH), which are still employed to name primary
tumors of LCs.
Dermal dendritic cells were initially considered to be
dermal fibroblasts or fibrohystiocytes (nomenclature for
tissue resident macrophages) by pathologists and histolo-
gists until 1986 when Headington identified them as the
population of DCs resident in dermis (Headington, 1986).
However it was still difficult to distinguish DDC from
macrophages because phagocytosis had become an impor-
tant general criterion to differentiate macrophages from
DCs. Since macrophages and not DCs were considered to
be highly phagocytic (Steinman, 1991), it was difficult to
accept that DDC, which were able to efficiently phagocytose
hemosiderin and melanin, could qualify as DCs. Instead
they were considered cellular links between macrophages
and DCs and called dendrophages (reviewed by Nestle and
Nickoloff in 1995). Eventually studies demonstrated their
functional capacity to take up and process Ags, migrate to
lymphatic organs and efficiently activate naïve T cells, and
DDCs were redefined as the APC population resident in
dermis (reviewed by Nestle and Nickoloff in 1995). 
Judging a Book by Its Cover: Homogeneous
or Heterogeneous Population of Cutaneous
Dendritic Cells?
Skin Resident Dendritic Cells
A considerable obstacle facing DC biologists is the
challenge of appropriately associating phenotype with
function for these extremely plastic antigen presenting cells.
As APCs of myeloid origin, skin resident LCs and DDCs
have several features in common that are also shared with
other tissue resident DCs. These include 1) phenotypic
similarities including high levels of expression of the human
Major Hystocompatibility Complex class I (MHC-I) and class
II (MHC-II) molecules, DC-T cell adhesion molecules, and
co-stimulatory molecules, 2) their functional ability to inter-
nalize and process protein Ags, and 3) their high motility
which enables them to transport and present Ag to T cells in
lymphoid organs. They also share leukocyte myeloid
phenotypic markers including expression of CD45RO,
CD13, and CD33 and lack of expression of other lineage
specific markers such as CD3-, CD19, CD20, CD16 and
CD56 (reviewed by Larregina and Falo in 2001b). The
expression of CD14 molecule observed in human LCs in
some pathological conditions, as well as the expression of
the molecule F4/80 by murine LCs and CD68 by DDCs
represents further evidence of their myeloid origin shared
with other cells of the monocyte-macrophage lineage
(reviewed by Larregina and Falo in 2001b).
As DCs resident in the epidermis, LCs share some
characteristics with other epithelia resident DCs that are not
observed in DDCs. On the other hand DDCs share some
phemotypic and functional characteristics with other connec-
tive tissue DCs and macrophages that are not shared by
LCs. The differences observed between LCs and DDCs
have been very useful to distinguish these two cell popula-
tions in situ. However, to characterize the function of LCs vs.
DDCs after activation and skin emigration one needs to
consider two important aspects of DC biology. First, DC
plasticity results in phenotype and functional changes in
activated DCs. Second, phenotypic characteristics of human
and mouse skin DCs are different. Specific structural and
phenotypic characteristics of LCs and DDCs that can be
used to distinguish them are summarized in Table 1.
LCs resident in epithelia express membrane adenosine
triphosphatase (ATPase) CD1a and CD1c (reviewed by
Romani et al, 1991), E-cadherin which mediates their
attachment to keratinocytes (Tang et al, 1991), and the C-
type lectin Langerin (Valladeu et al, 2000). Ultrastructurally
the hallmark of LCs is the Birbeck granule (BG), a rod or
racket shaped trilaminar membrane structure which is a
subdomain of the endosomal recycling compartment
(McDermont et al, 2002). Although this classic LC identifying
structure has been known for several years, its function is
only now being discovered. BGs are now thought to be
involved in Ag uptake and internalization of Langerin and
CD1a molecules. Langerin is a Ca2+-dependent type II
trasmembrane protein with a single carbohydrate recogni-
tion domain, which is almost exclusively expressed by LC.
Ligation of Langerin by the specific mAb antibody DCGM4,
or mannan, results in the internalization of Langerin and the
generation of BGs (Valladeau et al, 2000, Plzak et al. 2002).
In human and mouse skin Langerin is observed in epidermal
LCs and in some dermal DCs that are possibly LCs in transit
migrating out of the skin (Ebner et al, 2004; Tripp et al.
2004). Langerin expression can be used as a marker to
differentiate LCs from DDC, however expression of Langerin
is not limited to epidermal LCs. In fact Langerin positive cells
have been observed in spleen, heart, liver and thymus
(Valladeau et al, 2002). It is possible that Langerin positive
Skin resident Skin migratory 
Feature LCs DDCs LCs DDCs
Birbeck Granule** Yes No Low No 
CD1a Molecules
CD1a* Yes No Low No
CD1b* No Yes No Yes 
CD1c* Low Low Low Low
CD1d** No Yes No Yes
C-Type Lectines
Langerin** (CD207) Yes No Yes/Low No
MRR** (CD206) No Yes No Yes
DEC 205** (CD205) Yes Yes Yes Yes
Membrane ATPase** Yes No Yes No
Factor XIIIa* No Yes No Yes
E-Cadherin** Yes No Low No
**: Expression only in human DCs, 
**: Expression in mouse and human DCs
TABLE 1:  Main differential characteristics of skin resident 
LCs and DDCs and changes observed after maturation 
and skin migration. 
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DCs are LCs that have reached the peripheral blood circu-
lation and homed to different organs, but this has not been
proven. The coordinated function of the CD1a and Langerin
molecules will be discussed later in this review. 
Most of the morphological and phenotypic characteristics
of epithelia resident LCs are dependent on the skin microen-
vironment which is rich in TGF-1. Expression of
E-cadherin, CD1a, and induction of BG formation are
dependent on TGF-1 (Strobel et al, 1996). Moreover, 
TGF-1 is crucial for the homing of LCs in the epidermis as
demonstrated by the absence of LCs in the epidermis of the 
TGF-1-/- mouse (Borkowski et al, 1996). Accordingly,
addition of TGF-1 to culture medium has been used to
generate LCs from peripheral blood monocytes (Geissman
et al, 1998) and from dendritic cell precursors resident in
dermis (Larregina et al, 2001c). 
Regardless of the specific common phenotypic markers
used to identify the population of epithelia resident LCs,
some differences among them have been described. In
humans, according to differences in the level of expression
of HLA-DR, two different LC populations can be observed in
the epidermis: a predominate DR+low population and a
DR+high population comprising 10-25% of LCs. Neither the
cause nor the significance of this increased expression of
DR in a subset of the resident LC population has been deter-
mined (Dezutter-Dambuyant et al, 1984). Probably these
DR+high cells correspond to a subpopulation of large, activat-
ed LCs that can be easily seen in freshly isolated epidermal
sheets, and not to a distinct DC population (Romani et al,
1991).
Another DC population described in the epidermis and
the upper dermis are the so called indeterminate cells which
are characterized by the absence of BG. In normal skin this
particular DC represents 2% of the total CD1a+ cell popula-
tion. Although there are some reservations (because the
apparent lack of BG could be due to a different incidence in
skin sectioning) these cells were thought to represent LCs
precursors (reviewed by Teunissen et al, 1997). A DC
population devoid of BG was described in epidermis of
human patients with atopic dermatitis and other chronic
inflammatory diseases. These dendritic cells, named IDECs
(inflammatory dendritic epithelial cells) are characterized by
high levels of expression of Fc-RI and CD36, low level
expression of Fc-RII (CD23), CD1a, and CD1b, and
absence of Lag Ag (Wollenberg et al, 1996). Interestingly,
IDECs are generally considered to be a distinct subset of
DCs rather than a different maturation stage of LCs. IDECs
were also related to an expansion, in pathological condi-
tions, of a population of indeterminate cells (reviewed by
Teunissen et al, 1997).
DDCs share some functions and molecular markers with
DCs homing to connective tissues, and with cells from the
monocyte macrophage lineage. In fact DDCs are phagocyt-
ic, they are positive for enzymatic markers such as 
non-specific estearase, -glucuronidase, and acid
phosphatase. Some but not all DDCs also express trypsin, 
 1 antitrypsin, chymotrypsin, and lysozyme and the
macrophage markers CD68, and CD36 (Headington, 1993). 
Similar to DCs homing to other connective tissues, DDCs
express macrophage mannose receptors (MMR), CD1b and
CD1d. DDCs can be distinguished from LCs, dermal
fibroblasts and macrophages by the expression of the
intracytoplasmic transglutaminase clotting factor XIIIa
(FXIIIa) (Headington et al, 1986 and Cerio et al, 1989).
However FXIIIa is not a specific marker for DDCs as it can
also be found in other cells, including endothelial cells
(Suvarna et al, 1993). 
Although different populations of DDC have been
described according to their anatomical situation in the
dermis, this geographic distinction does not yet appear to
correlate with functional or phenotypic differences (Nestle
and Nickoloff, 1995). According to CD34 expression DDCs
have been classified into two populations: CD34+FXIIIa+
located mainly in the dermal microvascular unit, and 
CD34- FXIIIa+ cells. So far the only unique relevance of
expression of CD34 molecule by DDCs is there abundance
in dermal neoplasms of spindle cells and in keloids 
(Nestle and Nickoloff, 1995). 
Activated or Migratory Dendritic Cells
DCs function as biosensors of their environment, and are
remarkably capable of adapting to changes in their anatom-
ical habitat. The nature of the activation stimulus that DCs
receive determines their subsequent cellular and functional
characteristics (Reviewed by Larregina and Falo 2001b).
After activation and migration, LCs loose the presence of BG
and down regulate the expression of CD1a, Langerin and
E-cadherin in their cell membranes. Taken together, these
changes make it difficult to distinguish skin migratory LCs
from skin migratory DDCs (Romani et al, 1991, Lenz et al,
1993). Expression of low levels of CD1a and intracellular
expression of Langerin by LCs, and expression of FXIIIa or
CD1b may be helpful to phenotypically differentiate LCs
from DDCs in humans. 
Human skin migratory DCs can perhaps best be catego-
rized by their functional ability to stimulate naïve T cells. For
this purpose, purification of skin migratory DCs from epider-
mal-dermal explants represents a unique and irreplaceable
experimental model that enables the interception of DCs on
their way to skin draining lymph nodes. Based on the
expression of FXIIIa, CD1a and CD14, three different
populations of DC migrate from dermal explants:
(1) FXIIIa-, CD1a+, CD14-, (2) FXIIIa+ CD1a-, CD14-,
(3) FXIIIa+/-, CD1a-, CD14+. In T cell allogeneic proliferation
assays, the first and second populations induced strong
stimulatory response, however, the third population
CD1a- CD14+ cells, induced a reduced level of T cell 
proliferation similar to that of circulating monocytes (Nestle
et al, 1993 and Nestle and Nickoloff, 1995). In a further
characterization of these skin migratory DCs we have
observed that whereas the populations of CD14- cells seem
to be fully mature DCs, the population of CD14+ cells repre-
sent a population of immature DCs precursors with potential
to differentiate into cells with LC phenotype, and to acquire
allogeneic T cell stimulatory function when cultured in the
presence of TGF-1, GM-CSF and IL-4 (Larregina et al.
2001c). These observations demonstrate that the cell
population of spontaneous human skin migratory DCs is
heterogeneous. These DC populations have different
maturation states that correlate with different T cell allostim-
ulatory capacity (Nestle et al, 1993: Larregina et al, 2001). 
In murine systems, distinguishing LCs from DDCs after
skin migration and homing to skin draining lymph nodes
remains difficult. Important obstacles include: 1) mice lack
the expression of CD1a-c molecules (reviewed by Brigl and
Brenner in 2004), 2) FXIIIa has not been described in mice,
and, 3) Abs recognizing murine Langerin are not yet
commercially available. Given these limitations, combina-
tions of different levels of expression of cell membrane
molecules such as E-cadherin, DEC-205 (CD205), CD11b,
and CD8 are being used to distinguish LC from DDCs and
lymph node resident DCs (Sandrine H et al, 2001). Given
the phenotypic plasticity of these cells, classification based
on a combination of relative levels of multiple markers is
complex, and may be somewhat artificial. Although these
distinctions appear to be reproducible, the functional utility of
this approach remains to be determined.
CHANGING PARADIGMS IN CUTANEOUS IMMUNOLOGY 3124 : 1 JANUARY 2005
Where do Langerhans Cells Really 
Come From?
LCs and DDCs represent an active mobile pool of leuco-
cytes. An important function of LCs and DDCs is to take up,
process, and transport foreign or self Ags from the skin,
where they reside, to secondary lymphoid organs where
they present those Ags to T cells. The kinetics of DC
mobilization from the skin has been studied during inflam-
matory and physiologic (or steady-state) conditions. Most
studies have focused on the factors controlling mobilization
of LCs under inflammatory conditions. Inflammatory condi-
tions are characterized by secretion of proinflammatory
cytokines and chemokines such as IL-1 and TNF- and
MIP-3 in the skin microenvironment which are responsible
for an accelerated and substantial LC migration (Enk et al,
1993; Cumberbach et al 1994, 1995 and 1997; Schwarzen-
berger and Udey, 1996; Charbonier et al 1999). Inflammato-
ry conditions used to study migration of skin DCs include:
tape striping (Holzman et al, 2004) UV radiation (Kang et al,
1995; Meunier et al, 1995) genetic immunization protocols
(reviewed by Larregina and Falo in 2000) skin sensitizers
(Cumberbach et al 1997), skin grafts (Larsen et al 1991) and
experimental models of ex-vivo skin explants (Lenz et al,
1993: Morelli et al, 1995 and 1996; Larregina et al, 2001a
and 2001c). 
Little is known regarding the signals that trigger and
control migration of skin DCs under steady state conditions.
It has been hypothesized that in the steady state skin
migratory DCs transporting self Ags are responsible for
maintaining the state of self tolerance (reviewed by Morelli
et al, 2001). The study of LC migration and repopulation
under non-inflammatory conditions has generally been limit-
ed by the lack of appropriate experimental models. Systems
used include the study of kinetics following the use of
X radiation in mouse and humans preceding bone marrow
transplants, and the use of parabiotic mice that share their
circulation for extended periods of time (Katz et al, 1979;
Krueger et al, 1983; Krueger and Emam 1984; Murphy et al,
1986; Merad et al, 2002). 
The magnitude of mobilization of skin DCs is markedly
different during inflammation than that which occurs during
the steady-state. During inflammation the number of DCs
decreases rapidly and dramatically in skin, and this corre-
lates with a rapid increase of DCs in skin draining lymph
nodes (reviewed by Jakob et al in 2001). Conversely, under
steady state conditions, lower numbers of skin migratory
DCs are observed in local draining lymph nodes without a
noticeable decrease in the number of skin epidermal LCs.
These observations have prompted investigators to look for
differences in repopulation mechanisms in the setting of
inflammation vs. the steady-state. 
The BM origin of LCs was demonstrated in 1979 (Katz 
et al, 1979) and during the following years it came to be
accepted that LCs were constantly and consistently
replaced by a mobile pool of circulating precursors derived
from BM. Although it has been definitively demonstrated that
LCs are derived from BM, the mechanism/s controlling the
population of the epidermis by LC precursors under steady
state or inflammatory conditions are less clear. In a recent
publication, Merad et al present provocative evidence
suggesting that whereas during inflammation, LCs are
indeed replaced by circulating BM precursors, a different
mechanism/s is/are responsible for the replacement of LCs
during the steady state (Merad et al, 2002). They demon-
strated that in lethally irradiated mice which received
congenic BM transplants, LCs remained of host origin for a
period of up to 18 months, whereas DCs in other organs
were replaced by cells bearing the phenotype of the donor
BM cells. In a second set of experiments they studied
parabiotic mice that shared a common blood circulation, and
found no mixing of LCs for up to six months after parabiosis.
They conclude that in the steady state blood-born precur-
sors are not recruited to the skin and they do not give rise to
LCs. As alternative mechanisms, they postulate that LCs are
either 1) long lived, 2) replaced by a skin resident precursor,
or 3) that proliferation of LCs locally might be sufficient to
replace the low number of skin migratory LCs. These results
appear to contradict previously published studies. To recon-
cile their results with previous observations the investigators
propose that because the previous studies relied on trans-
plantation of allogeneic or semiallogenic BM, there may
have been some degree of graft vs. host disease present,
simulating an environment more consistent with inflamma-
tion than steady state. While this may explain results from
the allogenic model, it is not clear why skin inflammation
would occur in similar experiments where F1 ➞ parental
grafts were used (Katz et al, 1979). 
These experiments presented by Merad et al did not
directly address the possibility of LC repopulation from a
population of skin resident DC precursors. In this regard we
have recently demonstrated that a migratory population of
CD14+ DCs might represent a direct precursor for skin
resident DCs. These cells, characterized by a phenotype of
CD14+ CD1aNeg/Low, HLA-DR+, differentiate into cells with 
LC characteristics in short term cultures in the presence of
TGF-1. Accordingly they developed Birbeck granules, 
up-regulate expression of Langerin, CD1a, and E-cadherin,
and they decrease their expression of CD14 and CCR6.
Using only TGF-1 during cultures, these cells differentiated
into immature LCs and remained poor stimulators of
allogeneic T cells. The addition of GM-CSF and IL-4 induced
maturation with further upregulation of the molecules CD86,
CD40 and CD54 and correlated with high allogeneic T cell
stimulatory capacity. Although we did not directly determine
in vivo which environment conditions (physiological and/or.
inflammatory) would stimulate or enable these DC precur-
sors to differentiate into LCs, this is the first time that a skin
resident precursor of DCs has been identified, and its identi-
fication is consistent with data supporting a proposed role for
a skin resident DC precursor in LC repopulation (Larregina
et al, 2001c). 
Clearly the issue of the origin of LCs has emerged again
with more questions than answers and more experiments
will be necessary to interpret the results obtained from
previous investigations. Why, in the absence of inflamma-
tion, are LCs resident in the epidermis replaced by different
mechanisms than those in other connective tissue or
secondary lymph nodes? Even more intriguing is the
question of why replacement of LCs resident in the skin is
different from that observed for other LCs resident in non-
stratified epithelia, including LC equivalents in the gut or
respiratory epithelia (reviewed by Lucas and MacPherson,
2002). In fact the kinetics and replacement of LCs from
these non-stratified epithelia follows the same pattern
observed for replacement of DCs resident in connective
tissue (Holt et al,1994). It seems that a very specialized
mechanism (and probably more than one) might account for
the replacement of LCs resident in stratified epithelia,
however the physiological significance of this has not been
elucidated. Figure 1 summarizes the events taking place
during the repopulation of connective tissue resident DCs
and epithelia resident LCs, including those from the skin.
What Do Skin Dendritic Cells Really Do?
LCs and DDCs are professional APCs. Their capacity for
Ag processing and presentation has been broadly studied
and confirmed. Recent advances in the study of DC function
have both confirmed and challenged the established
paradigms. Intriguingly, a variety of recent studies are
suggesting that some of the immune functions attributed to
LCs are actually accomplished by other DC populations. For
example, plasmacytoid DCs (pDCs) are more sensitive than
myeloid DCs (including LCs and DDCs) to some danger
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signals. pDCs express of a broader pattern of toll like recep-
tors (TLRs) and respond to TLR ligation with secretion of
type I IFNs that are crucial for the development of antiviral
responses (Cella et al, 2000; Farkas et al, 2001; Wollenberg
et al, 2002). Another type of possibly underappreciated DC
is the inflammatory dendritic epidermal cell (IDEC). IDECs
are thought to be the main effectors in chronic cutaneous
inflammatory diseases. They produce and secrete IL-12 and
are thought to be responsible for the switch from a Th2
response to a Th1 response observed in chronic phase of
atopic dermatitis (Wollenberg et al, 1996 and 1998; Novak
et al, 2004). It has been shown that DDCs can replace LCs
in induction of contact sensitization and presentation of
tetanus toxin, and that they can induce protective Th1
responses to herpes simplex virus-2 and to leishmania,
when LCs do not (Grabbe et al, 1995, Nestle et al, 1998;
Baldwin et al, 2001; Zhao et al, 2003). Perhaps most
dramatically, several lines of new evidence suggest that
cross-presentation of viral Ag or self-Ag, and the resulting
cross-priming or cross-tolerization of CD8+ T cells, seems to
be an exclusive function of a population CD8+ DCs resident
in secondary lymphoid organs that does not include skin
derived DCs (Allan et al, 2003). Even the immunostimulato-
ry function of LCs in genetic immunization has recently been
questioned (Heath et al, 2004). On the other hand, new
evidence emphasizes the importance of relatively new
functions ascribed to cutaneous DCs. This includes
evidence elucidating the role of skin derived DCs in the
processing and presentation of non-protein antigens, and
recent studies that emphasize the seemingly contradictory
role of skin derived DCs in the maintenance of self-toler-
ance. These provocative new findings, and others like them,
have introduced a new level of excitement into cutaneous
immunology, and provide an enticing challenge. How do we
reconcile this new evidence with established principles? 
Starting at the beginning, the immune stimulatory
function of DCs was discovered in the allogeneic model of
Ag presentation using the non-plastic adherent fraction of
spleen cells (DCs) (Steinman and Chon 1973). Shortly after-
wards LCs were described as the APCs resident in the skin
(Silverberg et al, 1976). Since then most of the experiments
performed to determine the function of DCs were focused on
the stimulatory capacity of DCs, particularly LCs. However,
as it was discussed recently by Nickoloff, there is another
function of skin DCs that has been less explored: their
regulatory and antinflammatory activity (Nickoloff, 2002).
This contradictory, but perhaps not unexpected function of
an APC is important for the maintenance of the skin in its
steady state. In fact the skin microenvironment is constantly
exposed to physiological and pathological changes. In
response to these changes LCs have evolved to respond to
danger signals while controlling the intensity of immune or
inflammatory responses necessary to maintain homeosta-
sis. Any discussion of DC function must include those
regulatory functions that help to maintain the homeostasis of
the skin as well as those immunostimulatory functions
generated in response to “danger signals”.
Maintaining Homeostasis: the tolerogenic
function of skin DCs.
The classical model has LCs and DDCs populating the
skin in a “resting” state, patrolling for the arrival of foreign
Ag. Once they see and capture an Ag, and receive a danger
signal, they are “activated”, enabling them to migrate to skin
draining lymph nodes where they express their ultimate
function by activating Ag specific T cells. Although this
model is very well supported and likely correct, it does not
account for the regulatory function of skin DCs (Morelli et al,
2001, Steinman et al, 2003). These regulatory functions are
performed to maintain the state of skin self tolerance as well
as to prevent or terminate excessive inflammatory
responses.
There is evidence that during the steady state, also
described as the absence of “danger”, LCs take up epider-
mal cell Ags including those contained in apoptotic
keratinocytes, and melanin and associated proteins from
neighboring melanocytes (Parr et al, 1991, Miyima 1966).
Indeed the presence of melanin in dendritic cells in skin
draining lymph nodes has been used to monitor transport of
self Ags by skin derived DCs under steady conditions
(Hemmi H et al, 2001; Yoshino et al, 2003). Given these
observations, since during the steady state cutaneous
autoimmune responses are not observed, it is reasonable to
speculate that LCs are involved in maintaining the state of
peripheral self tolerance to skin Ags. The transport of self
Ags from the skin to local draining lymph nodes during the
steady state seems to be regulated by TGF-1 dependent
LCs or DDCs, as this transport is lost in the TGF-1-/- mice
that lack LCs in the epidermis (Hemmi H et al, 2001).
Additionally, in steady conditions other mechanisms might
influence LC mobilization. One possible candidate involved
in physiologic migration of LCs might be IL-10. Low amounts
of IL-10 are spontaneously produced by keratinocytes in
normal skin and its secretion is dramatically increased after
a UVB irradiation dose that also functionally abrogates the
response to skin sensitizers (Niizeki and Streiling 1997).
Interestingly, IL-10 produced by melanomas induces migra-
tion of tumor resident LCs, and this mechanism has been
proposed to account in part for the immune evasion
observed in melanomas (Enk et al, 1997). 
Although soluble factors controlling the mobilization of
LCs during the steady state need to be investigated further,
it has recently been established that full maturation is not
required for LC migration (Geissman et al, 2002). Demon-
stration of migration of immature/semimature LCs out of the
skin is consistent with their potential tolerogenic function
under these same steady state conditions. Accordingly, self
Ags are transported by skin DCs to local draining lymph
nodes by a mechanism independent of CCL21/CCR7 signal-
ing (Yoshino et al, 2003). Since up regulation of CCR7 is
observed in LCs during inflammation it was postulated that
mechanisms controlling LC migration are different during the
steady state than during inflammation. Recently it has been
Figure 1: Population of different organs by dendritic cell
precursors:  A) During steady state and inflammation, epithe-
lia and connective tissue organs are populated by a circulating
pool of DC and LC precursors originating in bone marrow. 
B) However the population of the epidermis by LCs during
steady state conditions represents an exception in that they are
renewed by a skin resident precursor or by self dividing LCs. 
FIGURE 1
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shown that immature/semi-mature LCs accumulate in skin
draining lymph nodes of patients suffering from chronic
inflammatory skin diseases (Geissman et al, 2002).
Moreover we have described the migration of skin resident
CD14+ cells which represent an immature precursor of skin
DCs. Those cells migrate spontaneously from human skin
explants while maintaining their semi-mature phenotype and
demonstrate very low T cell stimulatory function (Larregina
et al, 2001c). Although in the last situation some minor
degree of inflammation cannot be completely ruled out, they
clearly demonstrate that full maturation of skin DCs is not a
requisite for their mobilization. 
Other factors that can induce tolerogenic LCs are neuro-
endocrine hormones and peptides involved in negative
regulation of the immune response. Accordingly the skin has
a physiological production of pro-opio-melanocortin (POMC)
and calcitonine gene related peptide (CGRP). POMC is a
precursor that can be cleaved into several bioactive
neuropeptides including -melanocyte stimulating hormone
(-MSH) and adrenocorticotropic hormone (ACTH)
(Schauer et al, 1994). -MSH that is produced by cebocytes
of the pilosebaceous unit (Böhm and Luger, 1998) antago-
nizes the pro-inflammatory effect of IL-1 and TNF, inhibits
the production of IFN by human lymphocytes, and induces
the secretion of IL-10 (Bhardwaj et al, 1996). Importantly, 
-MSH, is able to transform immature DC into tolerizing DC
capable of inducing regulatory T cells (Grabbe et al 1996
and Groux et al, 1997). In addition, nerve fibers expressing
CGRP are situated very close to LCs and purified CGRP
inhibits the antigen presenting function of cultured LCs
(Hosoi et al, 1993). Together these regulatory factors may
promote tolerogenic function in skin resident DCs character-
istic of the steady state.
Whereas LC migration transporting skin self Ags under
physiologic conditions might account for the maintenance of
peripheral self tolerance, other regulatory functions of LCs
have been described. In fact, LCs resident in the epidermis
have a regulatory function that counteracts the pro-inflam-
matory activity of surrounding keratinocytes (Nickoloff
2002). It has been demonstrated that a decreased number
of LCs in the epidermis correlates with more severe inflam-
matory responses. It has been shown that although LCs are
important for the sensitization phase of contact hypersensi-
tivity (CHS), depletion of LCs before the elicitation phase
dramatically increases the inflammatory response regard-
less of the depletion method employed (i.e.: UV-B light or
corticoids) (Grabbe et al,1995). Another example of the anti-
inflammatory function of LCs is the function of their
membrane ATPase. Although ATPase expression has been
broadly used as a specific marker for epidermal LCs, and
even to differentiate LCs from DDCs, the function of this
enzyme was not investigated until recently. In 2002 and
2003 Mizumoto et al, have described that mice lacking the
expression of the CD39 molecule have an enhanced skin
inflammatory response to chemical irritants. Interestingly,
the CD39 molecule has an associated ectoATPase/ADPase
activity that converts ATP and ADP into AMP which is then
converted to adenosine. In the epidermis, keratinocytes
release ATP and ADP in response to a variety of stimuli
including physical stretching, apoptosis and application of
skin irritants. By binding prurinergic type 2 receptors, ATP
regulates diverse functions including cell growth, apoptosis
and inflammation. The presence of ATPase (CD39)
molecules on the surface of LCs counteracts the inflamma-
tory effect induced by nucleotides released in the skin.
Together these observations strongly suggest that the
functions of LCs and probably DDCs are more complicated
than expected. In addition to acting as potent APCs, they
also play an important role in maintaining self-tolerance and
the homeostasis of the skin. 
Skin DCs as antigen presenting cells?
Indeed the best known function of DCs is their ability to
present foreign Ag and activate naïve T cells. Priming of
naïve T cells requires Ag presentation in the context of MHC
molecules and in the presence of appropriate co-stimulation.
These are distinctive properties of DCs, as priming of naïve
T cells is not usually performed by other APCs (i.e., B cells
or macrophages) (Banchereau and Steinman 1998). The
skin and mucous membranes are constantly exposed to
external Ags. LCs and DDCs are thought to be the initiators
of immune responses against antigens introduced through
the skin. To accomplish their APC function skin DCs are fully
equipped for Ag uptake, processing and presentation. This
includes their expression of high levels of MHC-class I, class
II and CD1 molecules, as well as T cell adhesion and co-
stimulatory molecules (reviewed by Larregina and 
Falo 2001a and b). 
The unique APC function of LCs and DDCs has been the
focus of intense study for the purpose of vaccine develop-
ment and immunotherapy, including immunizations against
tumors and infectious diseases. For these purposes, the
mechanism/s involved in the priming of CD8+ T cells is of
considerable importance, since CD8+ T cells are the main
effector T cell population that recognize and eliminate tumor
cells and infected cells bearing MHC-class I bound peptides
(Yedwell and Bennik 1992, York and Rock, 1996). While it is
very well established that that skin DCs can efficiently
activate both CD4+ Th cells and CD8+ cytotoxic T cells
(CTLs), recent studies raise the question of whether or not,
in some circumstances, they actually do (Heath et al, 2004).
Both LCs and DDCs are able to prime different popula-
tions of naïve T cells against haptens, peptides, and 
non-peptide Ags (reviewed by Maurer and Stingl in 2002).
Different T cell populations that are primed by DCs, includ-
ing skin DCs, are CD4+ Th cells, CD8+ CTLs and CD4/CD8
double negative NK-T cells (Celluzzi et al 1996, Celluzzi and
Falo Jr, 1997; Brigl and Brenner 2004). Depending on the
mechanism of acquisition of Ag, two different pathways for
Ag presentation have been described. The endogenous
pathway of Ag processing refers to the processing of
endogenously synthesized cell proteins, including self cell
proteins and those foreign antigens synthesized following
viral infection or after inoculation of foreign DNA. The
processing of Ag through the endogenous pathway results
in loading of Ag peptides in the groves of MHC-class I
molecules (York and Rock 1996). In contrast, exogenous
extracellular antigens internalized through the exogenous or
endocytic pathway, are typically processed through the
MHC class II restricted pathway. Peptides derived from
exogenous proteins are presented in association with MHC-
class II molecules, and lipid Ags are presented in the context
of CD1 molecules (reviewed by Watts in 2004). Peptide Ags
presented in the context of MHC-II or MHC-I molecules are
recognized by CD4+Th cells or CD8+ CTLs respectively.
Whereas Ags presented in the context of CD1a molecules
are recognized by CD1 restricted T cells including 
bearing TCR CD4+ and CD8+ cells and NK-T cells (Exley 
et al 1997, Brigl and Brenner 2004). Although the molecular
basis for Ag presentation by skin DCs through the MHC-I
and II restricted processing pathways has been, and contin-
ues to be the subject of considerable study, the mechanisms
by which LCs or DDCs present non-protein Ag in the context
of CD1 molecules are just now being elucidated. 
The emerging role of skin dendritic cells in
the presentation of non-protein antigens.
LCs are characterized by the presence of CD1
molecules, BG and more recently by expression of Langerin.
Human LCs express CD1a and CD1c molecules, whereas
DDCs lack Langerin and BG, and express CD1b molecules
and macrophage mannose receptors (Brigl and Brenner
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2004; Mizumoto and Takashima, 2004). Recent studies
have demonstrated that these cellular structures and
molecules are not only differential markers for LCs and
DDCs, but are important functionally as interrelated compo-
nents of the Ag processing and presenting machinery in the
context of CD1 molecules (Hunger et al, 2004). 
CD1 is a family of molecules involved in the presentation
of self and foreign lipids and glycolipid Ags to T cells
(reviewed in Porcelli and Modlin, 1999). CD1a, CD1b and
CD1c are the members of type 1 isoforms of the CD1 family
of molecules. They are mainly expressed by APCs, and can
be recognized by CD4+ T-cells and CD8+ T cells bearing the
 TCR. CD1d includes a group of molecules of the type 2
isoforms of the CD1 family (Brigl and Brenner 2004). CD1d
is the only member of the CD1 family that is expressed in
both mouse and human APCs. Ags presented in the context
of CD1d are recognized by double negative NK-T cells. Ags
that can be presented in the context of CD1 molecules are
shown in Table 2.
CD1 molecules associate with 2 microglobulin in the
ER, are inserted into the cell membrane, and a tyrosine rich
motif present in their intracellular tail directs their sorting into
different endocytic compartments. CD1a molecules lack the
tyrosine rich intracytoplasmic tail and are internalized into
BG. Inside BGs CD1a molecules are loaded with microbial
glycolipids (Hunger et al 2004). The process of loading of
lipid Ag into CD1a molecules does not require acidification
(Watts, 2004). Most of the lipids that have been identified to
date as presented in the context of CD1a molecules are
present in the cell wall of mycobacterium such as
mycobactin from Mycobacterium tuberculosis (Pena- Cruz
et al, 2004) and mycolyl arabinogalactan peptidoglycan
(MAGP) from Mycobacterium leprae. Interestingly specific
blockade of Langerin in LCs inhibits Ag uptake and prolifer-
ation of MAGP specific T cell clones strongly suggesting that
MAGP is internalized into BG after binding to Langerin
(Hunger et al 2004). In a recent study it has been observed
that Langerin also mediates internalization of molecules
containing carbohydrates such as fucose, N-acetil-
glusamine and mannose into BG (Plzak et al, 2002). 
Importantly, human LCs efficiently present glycolipids from
Mycobacterium tuberculosis and from Mycobacterium
leprae in a CD1a restricted manner to specific T cell clones. 
CD1b molecules are expressed in human DDCs and in
DCs derived from peripheral blood monocytes. CD1b
molecules exported to the cell membrane are internalized in
clathrin-coated pits. CD1b molecules have a long intracyto-
plasmic tail rich in tyrosine motifs which directs their sorting
into early endosomes, late endosomes/lysosomes and in to
MHC-class II rich compartments by binding the adaptor
proteins AP2 and AP3. In the lysosome compartment CD1b
molecules bind to different glucolipids including lipoarabino-
mannan (LAM), phosphatidylinositol mannoside and
glucose-monomycolate (GMM) found mainly in the cell wall
of mycobacterias (Brigl and Brenner 2004). These glycol-
ipids can be internalized by binding MMR and DC-SIGN
expressed on the cell surface of DDCs. Indeed MMRs and
DC-SIGN (expressed by DDCs and not by LCs) have an
intracytoplasmic tail with tyrosine rich motifs that direct the
sorting of these molecules into endosomes and lysosomes.
Co-localization of MMRs and DC-SIGN with CD1b
molecules might account for loading of glycolipids in CD1b
groves (Mizumoto and Takashima 2004). 
Other molecules from the CD1 family are CD1c and
CD1d. CD1c is expressed at low levels in both LCs and
DDCs. Whereas CD1a and CD1b localize in totally different
cellular compartments, the CD1c distribution overlaps with
both CD1a and CD1b (Mizumoto and Takashima 2004).
CD1d molecules are expressed at low levels on DDCs and
not in LCs (Nickolof et al 1998). CD1d is the only CD1
molecule expressed in both mouse and human APCs
(Spada et al, 1999). CD1d restricted NK-T cells, recognize
the glycosphingolipid a-galactosilceramide (GalCer)
(Brossay et al, 1998). The immunologic significance in
mammalians of this molecule remains to be determined.
However it is known that activation of NK T cells through
CD1d results in production of IFN- and promotes cellular
immune responses (reviewed by Brigl and Brenner 2004).
Our current understanding of CD1 restricted antigen
processing pathways is summarized schematically in 
Figure 2. The ongoing analysis of CD1 mediated stimulation
of T cells and the study of the CD1 restricted T cell effector
functions is a broad new area of research which will allow a
better understanding of the role of skin dendritic cells and











Figure 2: Presentation of lipid antigen in the context of
CD1 molecules:   A) CD1a molecules expressed by epidermal
LCs are synthesized in the ER (1) and exported to the cell
membrane (2). CD1a molecules lack the intracytoplasmic tail rich
on tyrosine residues and are internalized into BGs (3). Langerin
molecules bind to glycolipid Ags such us those from mycobacteri-
um leprae and mycobacterium tuberculosis cell walls and are
also internalized into BGs (3).  Inside BGs, CD1a molecules are
loaded with glycolipids and are recycled to the cell membrane for
presentation to CD1a restricted CD4 and CD8 T cells (4).
FIGURE 2
CD1 molecule Foreign Antigens Self Antigens
CD1a mycobactin  (M tuberculosis) sulfatide
MAGP (M leprae)











* Antigens from mycobacterium wall.
Modified from: Brigl M. and Brenner M. Ann.Rev.Immunol 2004.
TABLE 2:  Antigens recognized by T cells in the context of CD1
molecules
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Cross priming and the controversial role of
skin derived DCs vs. lymph node resident
DCs in the presentation of cutaneous
antigens.
As described previously there are two traditional
pathways for protein Ag processing and presentation: 1) the
endocytic pathway which results in loading of exogenous
Ags into MHC-II molecules for presentation to CD4+ T-cells
and, 2) the endogenous pathway which results in presenta-
tion of endogenous Ag in the context of MHC-I molecules to
CD8+ T-cells. A third pathway of antigen uptake and presen-
tation, known as “cross-presentation” represents an impor-
tant mechanism for the presentation of exogenous Ag to
CD8+ T cells through a process called “cross-priming”. It has
been demonstrated that certain extracellular Ags, like those
contained in particulate material or apoptotic cells, can
efficiently access the endogenous pathway for Ag process-
ing and be presented in the context of MHC-class I
molecules (Kovacsovics-Bankowski and Rock 1995, Falo Jr.
et al, 1995; Celluzzi and Falo, 1998; Albert et al, 1998 Shen
et al, 2004). Since presentation of antigen in the context of
MHC class I molecules results in induction of antigen-specif-
ic CD8+ CTLs, understanding the mechanism/s of cross-
priming has important relevance for the development of
immunization strategies against tumors and infectious
diseases.
As an example supporting a role for skin-derived DCs in
cross-presentation, our laboratory and others have demon-
strated that biolistic genetic immunization is an effective
strategy to generate robust and persistent CTL responses
against DNA encoded protein Ags in both mouse and
human models (Condon et al, 1966; Larregina et al, 2001a).
Paradoxically, skin transfection results in the induction of
potent and effective immunity despite the fact that only a
small number of directly transfected skin derived DCs are
present in draining lymph nodes (Condon et al, 1966;
Porgador et al, 1998; Akbari et al 1999). In these systems,
expression of transgenic proteins is mainly observed in
keratinocytes. Because of the high expression of transgenic
proteins by keratinocytes, it is tempting to speculate that
LCs resident in the epidermis could take up transgenic Ags
from neighboring keratinocytes, and then cross-present
these exogenous antigens to cross prime CD8+ T cells in the
lymph nodes. It is well established that dendritic cells can
efficiently internalize and present apoptotic bodies or necrot-
ic debris from dead and dying cells. We have shown direct-
ly that DCs can efficiently internalize and cross-present
antigens from neighboring live cells through a contact
dependent mechanism (Celluzzi and Falo, 1998). Important-
ly, experiments using the cell type specific promoter K14 to
express transgenic Ags exclusively in keratinocytes 
definitively demonstrated that the cross-priming mechanism
can be sufficient to induce strong CTL responses (Cho et al
2001). The relative contribution of directly transfected LCs
vs. cross-presenting LCs in determining the nature and
duration of the immune response remains to be determined.
Regardless of the relative contributions of direct presenta-
tion and cross-presentation, it seems likely and has gener-
ally been assumed that a skin derived DC, either presenting
endogenous transgenic antigen directly, or cross-presenting
antigen taken-up from neighboring keratinocytes, is respon-
sible for stimulating T-cells in the draining lymph nodes. 
Importantly, the mechanism of cross-priming can be
utilized not only to activate CD8+ T cells, but also to induce
cross-tolerance to self Ags (reviewed by Heath and Carbone
in 2001). Indeed tissue resident DCs including LCs are able
to take up self proteins from neighboring cells, or to inter-
nalize apoptotic keratinocytes and transport these antigens
to the draining lymph nodes (Parr et al 1991; Yoshino et al
2003). Considerable evidence suggests that LCs and
probably DDCs are the main APC populations responsible
for delivering skin-derived antigens to the lymph nodes and
presumably mediating cross-presentation of skin derived
Ags to CD8+ T cells in either an immunogenic or tolerogenic
fashion.
In contrast to the existing paradigm, very recent studies
suggest that cross priming of CD8+ T cells is performed by
CD8+ DCs resident in the T cell areas of secondary lymphat-
ic organs and not by skin derived DCs (Allan et al, 2003).
Several Ags have been shown to be cross-presented to
CD8+ T cells by these resident CD8+ DCs, including many
viral Ags introduced via the skin, and the well-studied model
antigen chicken ovalbumin (OVA) (reviewed by Heath et al,
2004). It is important to note that many of these models rely
on viral infection of skin and skin derived DCs, which can
alter the ability of these DCs to present Ag directly, or
change their role in antigen presentation. Nevertheless, as
DCs in skin do not appear to express CD8+, an intriguing
interpretation of these results is that these antigens deliv-
ered via the skin are cross-presented by these lymph node
resident CD8+ DCs, and not significantly presented by skin
derived dendritic cells. 
Interestingly, our laboratory has demonstrated that
allogeneic apoptotic cell bodies, injected intravenously into
mice, are taken up by CD11b+ myeloid DCs in the marginal
zone of the spleen and transported to the T-cell areas for
presentation to T cells (Morelli et al, 2003). Importantly, in
agreement with these recent results, presentation of the
alloantigen was mainly performed by CD8+ DCs which lack
the CD11b molecule. Interestingly, we were unable to




















































Figure 2: Presentation of lipid antigen in the context of
CD1 molecules:   B) CD1b, CD1c and CD1d molecules
synthesized in the ER are exported to the cell membrane and
are internalized in coated pit endocytic vesicles. Due to the
presence of intracytoplasmic tyrosine rich motifs, these CD1
molecules bind AP 2 proteins and localize into EE, LE and
Lysosomes. CD1b molecules also bind AP 3 and localized
further in MHCIIc. Different c-type lectins also containing
tyrosine rich motifs, including MMR and DC-SIGN, co-localize
with CD1 molecules. CD1 molecules loaded with glycolipids are
recycled to the cell surface for presentation to CD1b and CD1c
restricted CD4 and CD8 T cells, and in the case of CD1d to
CD1d restricted NK T cells. AP 2, AP 3: adaptor of protein
complex 2 and 3, BG: Birberck granule, ER: endoplasmic 
reticulum, EE: early endosome, LE: late endosome, Ly:
lysosomes, MHCIIc: Major Hystocompatibility Molecules class II
complexes, MMR macrophage mannose receptors, DC-SIGN:
DC-specific intercellular adhesion molecule (ICAM)-3-grabbing
nonintegrin, YXXZ: tyrosine rich intracytoplasmic tail.
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CD8+ CD11b- DCs. Moreover, using “in vitro” co-cultures of
CD8+ DCs with apoptotic bodies, we were unable to
demonstrate internalization of apoptotic cells by CD8+DCs.
While these negative results are by no means definitive, one
interpretation is that the CD8 molecule could be up-regulat-
ed by myeloid DCs following their traffic to the T cell areas
of the spleen. Consistent with this possibility, up-regulation
of the CD8+ molecule by myeloid DCs has been described
by several groups (Traver D et al 2000, del Hoyo et al, 2002;
Ardavin 2003). It has also been suggested that low expres-
sion of the CD8 molecule by myeloid DCs during “in vivo”
experiments can be explained through the transfer of CD8
molecules from neighboring T cells to DCs (Heath et al
2004). Other recent studies suggest that LCs can acquire
high expression of the CD8 chain after maturation through
signaling of the CD40 molecule, even in the absence of
CD8+ T cells in the microenvironment (Anjuere et al, 2000).
Despite convincing evidence that CD8+ DCs play a critical
role in the presentation of viral antigens from infected skin,
these studies suggest that definitively ruling out a role for
skin derived DCs in the presentation of viral antigens from
infected skin, or the presentation of antigens introduced
through the skin in other non-infectious settings, may still be
premature.
If indeed CD8+ DCs resident in secondary lymphoid
organs are responsible for cross-priming CD8+ T-cells to
antigens delivered through the skin, their range of function
would appear to be extraordinarily diverse. CD8+ DCs
could both cross-tolerize CD8+ T cells to self Ags under
certain circumstances, while activating T-cells through
cross-priming under others. In support of their role in induc-
ing cross-tolerance, it has been demonstrated that CD8+
DCs can down regulate the immune response against
allogeneic CD4+ T cells via Fas/FasL induced apoptosis of
responders CD4 T cells (Suss and Shortman 1996). Similar-
ly CD8+ DCs can down regulate the CTL response of
allogeneic naïve CD8+ cells by limiting their production of 
IL-2 (Kronin et al, 1996). Whether more than one population
of CD8+ DCs accounts for these diverse functions has not
been determined.
Ending at the beginning
We began the discussion with the functional definition of
dendritic cells. Classically, DCs, including those resident in
peripheral tissues, have been defined by their ability to: i)
take up and process Ags in peripheral tissues where they
reside, ii) migrate and transport those Ags from periphery to
secondary lymphoid organs and iii) stimulate naïve T cells
(Banchereau and Steinman, 1998). To end at the beginning,
one need only to consider the example of one of the intrigu-
ing interpretations of this new data - that CD8+ DCs
resident in secondary lymphoid organs, and not skin derived
DCs, are responsible for cross-priming CD8+ T-cells to
antigens delivered through the skin. 
Such an interpretation would require alternative mech-
anisms to explain how such lymph node resident DCs could
efficiently access cutaneous antigens. Could extracellular
antigens, or antigen released from dead or dying skin cells
drain through the lymphatics to be captured by lymph node
resident CD8+ DCs, obviating the need for skin DCs for
antigen delivery? Alternatively, could DCs that are express-
ing foreign antigens, either through transfection or infection,
traffic to the draining nodes and transfer antigen to the
appropriate resident CD8+ DCs for cross-presentation,
redefining the role the skin DCs as that of a messenger? Or,
as suggested by the genetic immunization model described
above, could it be possible that a skin derived DC that has
taken up an exogenous antigen either from the extracellular
space, or from a neighboring keratinocyte, could then travel
to the lymph node and transfer that antigen to a second DC,
in essence a process of “double-cross-presentation”? While
we and others have shown that DCs can efficiently extract
antigens from live cells for presentation, whether such a
process, which would need to occur twice, would be efficient
enough to generate a systemic immune response in vivo
remains an open question (Celluzzi and Falo, 1998,
Harshyne et al, 2001). 
Clearly these new results have raised more questions
than they have answered. Today we favor a functional
model that depends on the unique plasticity of DCs, rather
than the existence of multiple distinct subsets with preor-
dained functional programs. Unlike most cell types, DC
function actually depends in part on their ability remain in a
not fully differentiated and highly reactive state. It would
seem logical that such “immature” DCs in the periphery do
not have preordained effector functions, but instead are
receptive to stimuli and reactive to their environment. In this
way, skin DCs could “inform” the central immune system of
conditions in the periphery. The same could be said for DCs
resident in lymph nodes or spleen - their function may adapt
to the conditions in their environment. Taken to the extreme,
it is possible that the function and/or phenotypic markers of
a skin derived DCs could change as they arrive in the lymph
nodes, and continue to adapt as they travel through the
lymphatic architecture. Many of these issues remain
unresolved, inspiring us all to work for tomorrow’s results.
There appears to be a lot more work to do.
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